These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 37425694)
21. Assessing the Effectiveness of Curative Benznidazole Treatment in Preventing Chronic Cardiac Pathology in Experimental Models of Chagas Disease. Francisco AF; Jayawardhana S; Taylor MC; Lewis MD; Kelly JM Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30082291 [TBL] [Abstract][Full Text] [Related]
22. Prodrugs as new therapies against Chagas disease: in vivo synergy between Trypanosoma cruzi proline racemase inhibitors and benznidazole. de Melo GD; Coatnoan N; Gouault N; Cupif JF; Renault J; Cosson A; Uriac P; Blondel A; Minoprio P J Glob Antimicrob Resist; 2022 Mar; 28():84-89. PubMed ID: 34929377 [TBL] [Abstract][Full Text] [Related]
23. Metabolomics, lipidomics and proteomics profiling of myoblasts infected with Trypanosoma cruzi after treatment with different drugs against Chagas disease. Hennig K; Abi-Ghanem J; Bunescu A; Meniche X; Biliaut E; Ouattara AD; Lewis MD; Kelly JM; Braillard S; Courtemanche G; Chatelain E; Béquet F Metabolomics; 2019 Aug; 15(9):117. PubMed ID: 31440849 [TBL] [Abstract][Full Text] [Related]
24. Parasitemia Levels in Trypanosoma cruzi Infection in Spain, an Area Where the Disease Is Not Endemic: Trends by Different Molecular Approaches. Flores-Chavez MD; Abras A; Ballart C; Ibáñez-Perez I; Perez-Gordillo P; Gállego M; Muñoz C; Moure Z; Sulleiro E; Nieto J; García Diez E; Simón L; Cruz I; Picado A Microbiol Spectr; 2022 Oct; 10(5):e0262822. PubMed ID: 36190410 [TBL] [Abstract][Full Text] [Related]
25. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
26. Benznidazole and amiodarone combined treatment attenuates cytoskeletal damage in Barbosa JMC; Pedra-Rezende Y; Pereira LD; de Melo TG; Barbosa HS; Lannes-Vieira J; de Castro SL; Daliry A; Salomão K Front Cell Infect Microbiol; 2022; 12():975931. PubMed ID: 36093188 [TBL] [Abstract][Full Text] [Related]
27. Assessment of a combined treatment with a therapeutic vaccine and benznidazole for the Trypanosoma cruzi chronic infection. Prochetto E; Bontempi I; Rodeles L; Cabrera G; Vicco M; Cacik P; Pacini MF; Pérez Gianeselli M; Pérez AR; Marcipar I Acta Trop; 2022 May; 229():106334. PubMed ID: 35101415 [TBL] [Abstract][Full Text] [Related]
28. Experimental models in Chagas disease: a review of the methodologies applied for screening compounds against Trypanosoma cruzi. Fonseca-Berzal C; Arán VJ; Escario JA; Gómez-Barrio A Parasitol Res; 2018 Nov; 117(11):3367-3380. PubMed ID: 30232605 [TBL] [Abstract][Full Text] [Related]
29. Changes in the immune response after treatment with benznidazole versus no treatment in patients with chronic indeterminate Chagas disease. Vallejo A; Monge-Maillo B; Gutiérrez C; Norman FF; López-Vélez R; Pérez-Molina JA Acta Trop; 2016 Dec; 164():117-124. PubMed ID: 27619190 [TBL] [Abstract][Full Text] [Related]
30. Transcriptomic analysis of benznidazole-resistant and susceptible Trypanosoma cruzi populations. Lima DA; Gonçalves LO; Reis-Cunha JL; Guimarães PAS; Ruiz JC; Liarte DB; Murta SMF Parasit Vectors; 2023 May; 16(1):167. PubMed ID: 37217925 [TBL] [Abstract][Full Text] [Related]